{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:30:32Z","timestamp":1789644632999,"version":"4.0.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,27]]},"DOI":"10.18632\/oncotarget.13262","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T18:05:51Z","timestamp":1478801151000},"page":"85937-85947","source":"Crossref","is-referenced-by-count":12,"title":["Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies"],"prefix":"10.18632","volume":"7","author":[{"given":"Sarah","family":"Bertoli","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"},{"name":"Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sterin","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"},{"name":"Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vergez","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France"},{"name":"Laboratoire d\u2019H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sarry","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[{"name":"Service d\u2019Epid\u00e9miologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"},{"name":"UMR 1027, INSERM-Universit\u00e9 de Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pr\u00e9bet","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Institut Paoli-Calmettes, Marseille, France"},{"name":"D\u00e9partement d'Oncologie Mol\u00e9culaire, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, UMR1068 Inserm, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Institut Paoli-Calmettes, Marseille, France"},{"name":"D\u00e9partement d'Oncologie Mol\u00e9culaire, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, UMR1068 Inserm, Marseille, France"},{"name":"Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"},{"name":"Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Brunning","year":"2002","journal-title":"Blood"},{"key":"2","first-page":"109","volume-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa042715","article-title":"DNA topoisomerase II in therapy-related acute promyelocytic leukemia","volume":"352","author":"Osheroff","year":"2005","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia: report of four cases possibly related to melphalan","volume":"283","author":"Bayrd","year":"1970","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMe048336","article-title":"Insights into leukemogenesis from therapy-related leukemia","volume":"352","author":"Pedersen-Bjergaard","year":"2005","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJM198907203210302","article-title":"Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia","volume":"321","author":"Murphy","year":"1989","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2009.11.025","article-title":"Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia","volume":"184","author":"Le Beau","year":"2010","journal-title":"Chem Biol Interact"},{"key":"8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1212\/WNL.59.6.954","article-title":"Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS","volume":"59","author":"Clanet","year":"2002","journal-title":"Neurology"},{"key":"9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Klco","year":"2015","journal-title":"Nature"},{"key":"10","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Curtis","year":"2013","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Stockelberg","year":"2015","journal-title":"Am J Hematol"},{"key":"12","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.23966","article-title":"Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias","volume":"90","author":"Niscola","year":"2015","journal-title":"Am J Hematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study","volume":"33","author":"N\u00f8rgaard","year":"2015","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstr\u00f6m macroglobulinemia: An analysis of the SEER database","volume":"121","author":"Treon","year":"2015","journal-title":"Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Fraumeni","year":"2010","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Fritschi","year":"2011","journal-title":"Br J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am J Hematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Schlegelberger","year":"2011","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ajh.23605","article-title":"Predictive factors for latency period a prognostic model for survival in patients with therapy-related acute myeloid leukemia","volume":"89","author":"Sekeres","year":"2014","journal-title":"Am J Hematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.bmt.1705547","article-title":"Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?","volume":"39","author":"Fenske","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"21","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/leu.2013.368","article-title":"The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia","volume":"28","author":"Walter","year":"2014","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Klimek","year":"2013","journal-title":"Haematologica"},{"key":"23","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.3324\/haematol.2014.118034","article-title":"High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia","volume":"100","author":"Hellstr\u00f6m-Lindberg","year":"2015","journal-title":"Haematologica"},{"key":"24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindeman","year":"2015","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Schiffer","year":"2001","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.biopha.2011.04.006","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide","volume":"65","author":"Palibrk","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/modpathol.2011.158","article-title":"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"25","author":"Wang","year":"2012","journal-title":"Mod Pathol"},{"key":"28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Tausch","year":"2016","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts","volume":"126","author":"Bernal del Castillo","year":"2015","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.23848","article-title":"R\u00e9cherC. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network","volume":"89","author":"Huguet","year":"2014","journal-title":"Am J Hematol"},{"key":"31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-5-44","article-title":"Outcome of therapy-related myeloid neoplasms treated with azacitidine","volume":"5","author":"D\u2019Al\u00f2","year":"2012","journal-title":"J Hematol Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.leukres.2013.02.014","article-title":"Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS\/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.leukres.2012.12.012","article-title":"Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models","volume":"37","author":"Komrokji","year":"2013","journal-title":"Leuk Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Burnett","year":"2010","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Sarry","year":"2013","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3109\/10428194.2012.685733","article-title":"Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction","volume":"53","author":"Vey","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"37","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1002\/ajh.23884","article-title":"Comparison of 60 or 90 mg\/m of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics","volume":"90","author":"Vey","year":"2015","journal-title":"Am J Hematol"},{"key":"38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Niederwieser","year":"2010","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T16:36:03Z","timestamp":1589301363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":38,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016,12,27]]}},"alternative-id":["13262","27852053"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13262","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}